Michael Needle, MD and Chief Medical Officer for AVEO Oncology gives an update for the Phase 3 TIVO-3 trial, a randomized, controlled,
multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
TIVO-3 Trial Status
